Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

• T cell receptors (TCRs), in JRA, 482
• T cells
  • adhesion, in rheumatoid synovitis, 1365
  • CD95 signaling mutant and, 1047
  • CD49d γ/δ, in SSc, 327
  • cytokines, single-cell analysis in RA, 1669
  • Fas-sensitive, 1
  • in genetic regulation of pristane-induced arthritis in mice, 2022
  • hprt[minus] mutant, in RA, 1772
  • IFNγ production by, in RA, 306
  • inhibition of production of type I collagen by, 2039
  • lymphoma, osteolytic lesions in, 2275
  • memory, in SLE-associated glomerulonephritis, 335
  • naive, in SLE-associated glomerulonephritis, 335
  • in proteoglycan-induced polyarteritis, 1007
  • RA synovial antigen, recognition by CD4+, CD8[minus] clones, 92
  • receptor, in RA, 1906, 1911
  • receptor peptide vaccine, in RA, 1919
  • response to recombinant Yersinia antigens in reactive arthritis, 315
  • in SLE, 1456
  • stimulated, and MMP-1, TIMP-1, and PGE2 production, 1748
  • Vδ1+ in skin in SSc, 327
• Tax proteins
  • activation of synovial cells by soluble, 1995
  • autoantigens of, in human T cell leukemia virus type I, 101
• TCRα/β
  • in collagen-induced arthritis in mice, 256
  • in RA, 92
• Tendon friction rubs in SSc, predictive value of palpable, 186
• Tetanus toxoid (TT) vaccine, and antigen-specific antibody responses in SLE, 1828
• Tetrahydrocannabinol, antiinflammatory activity of, 163
• Tetramethylpentadecane, in genetic regulation of pristane-induced arthritis in mice, 2022
• Th1 cytokines
  • in aggrecan-induced polyarteritis, 1007
  • in RA, 48, 306, 1669
  • in reactive arthritis, 315
  • in SLE, 838
• Th2 balance and, sex steroids in, 1897
• Th2 balance in arthritis and, 1896
• Th2 cytokines
  • in RA, 48, 1669
  • in reactive arthritis, 315
• Th1 balance and, sex steroids in, 1897
• Th1 balance in arthritis and, 1896
• Thalidomide, amenorrhea in lupus and, 2273
• Thiopurine methyltransferase (TPMT), and azathioprine toxicity in RA, 1858
• Tight skin 2 mice, fibroblasts, procollagen gene regulation in, 2132
• Tissue factor (TF) expression, anticardiolipin antibodies and, 1420
• Tissue inhibitor of metalloproteinases 1 (TIMP-1)
  • cathepsin and matrix metalloproteinase expression in RA and OA and, 1378
  • oncostatin M in cartilage destruction and, 1760
  • in synoviocytes and fibroblasts, 1748
• Toe, arthritis in, as presentation in tuberculosis, 374
• Total joint arthroplasty, in RA, 1072
• Transcription factors
  • procollagen gene regulation in tight skin 2 mice and, 2132
  • in proteoglycan inhibition in cartilage destruction, 274
  • in RA, 48
• Transdermal photodynamic therapy (tPDT), in antigen-induced arthritis, 525
• Transfer RNA (tRNA), 1428, 1625
• Transforming growth factor β (TGFβ)
  • COMP synthesis induced by, 997
  • human cytomegalovirus associated with, 10
  • and monoclonal expansion of synoviocytes in RA, 1979
  • parathyroid hormone-related protein and, in articular chondrocytes, 2152
• Transient diplopia, in giant cell (temporal) arteritis, 26
• Transplantation
  • after allogeneic bone marrow, 453
  • lupus nephritis after renal, and cyclosporine, 678
  • peripheral blood stem cell, remission of SLE and, 2271
  • renal, in SLE, cyclosporine-era, 1438
  • repair and, articular cartilage, 1331
• Tripterygium wilfordii Hook F (TWHF), effect on induction of cyclooxygenase 2 and prostaglandin E2, 130
• Triptolide, effect on COX-2 and prostaglandin E2, 130
• Tuberculosis, arthritis in great right toe as clinical presentation of, 374
• Tumor necrosis factor α (TNFα)
  • on human articular chondrocytes, 1296
  • interferon-γ effects on protein in human chondrocytes and, 274
  • in motheaten mice with arthritis and pneumonitis, 139
  • in OA chondrocytes, 2165
  • oncostatin M in cartilage destruction and, 1760
  • polymorphisms and ankylosing spondylitis, 1489
  • in RA, and immunoregulation of inflammation by interleukin-11, 1388
  • in RA, and interleukin-1α induction of interleukin-11, 2004
  • in RA, modulation of vascular endothelial growth factor, 1258
  • in RA, with MTX and multiple anti-tumor necrosis factor α infusions, 1552
  • in rheumatoid nodules, 1783
  • in SLE, 205
  • in SSc, and HLA class II alleles in anti-topoisomerase I responders, 1306
• Tumor necrosis factor β (TNFβ), in leukemic arthritis, 1695
• Tumor necrosis factor receptor I (TNFRI)
  • in motheaten mice with arthritis and pneumonitis, 139
  • in murine cytomegalovirus SS-like disease, 2175
• Twins, ankylosing spondylitis in, 2085